Skip to main content
x
Recombinant Bromelain: A Novel Source on Anti-Cancer
tm286809651
Category of Technology / Product
  • Description
  • Intellectual Property
  • Corporate Information
  • Contact

This study observed the anti-cancer activity of recombinant bromelain produced by the DNA recombinant technology thus easing the purification steps. The in-vitro cytotoxicity assay was conducted on the recombinant bromelain treated and untreated breast cancer (MCR-7) and normal cell lines (Vero). Then the half maximal inhibitory concentration (IC50) on all samples were recorded. Commercial bromelain served as a control in this experiment. The IC50 for both enzymes are 0.29mg/mL and 0.27mg/mL for recombinant and commercial bromelain respectively. Based on the IC50 values, both recombinant and commercial bromelain, did affect the cell lines at high concentration which is more than 0.25 mg/mL. zthe IC50 obtained from MCF-7 cells treated with recombinant and commercial bromelain are 0.20mg/mL and 0.16mg/mL respectively. Therefore, recombinant bromelain behaves similarly to the commercial bromelain in their anti-cancer activity especially to the MCF-7 breast cancer and Vero cells lines.

Industrial Design
No
Trademarks
No
Patent
No
Other IP Protection
No
Organization Category
Address

International Islamic University Malaysia, P.O. Box 10,
53100 Kuala Lumpur
Kuala Lumpur
Malaysia

Full Name [1]
Azura Amid
Email [1]
azuraamid72@gmail.com